Authors highlighted the fact that, contrary to other common autoimmune diseases, vitiligo patients are submitted mainly to topical or local therapies, and not usually exposed to systemic immunomodulatory drugs such as cyclosporine, methotrexate, and tumor necrosis factor (TNF) inhibitors (commonly used to treat other autoimmune diseases). Here, TNF is linked to vitiligo.